Eli Lilly and Company

Advancements in Alzheimer's blood tests, AI, and drug safety

13 clusters · 64 sources · last updated about 22 hours ago

Latest: Alzheimer’s detection advances through AI and blood testing

Research into Alzheimer's biomarkers continues to evolve, with recent findings refining the utility of blood-based testing. While plasma p-tau217 remains a key indicator, studies suggest its predictive power in symptom-f

Eli Lilly retatrutide development and black market issues

9 clusters · 28 sources · last updated 2 days ago

Latest: Retatrutid research shows potential for obesity treatment

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in

GLP-1 obesity drug rollout and market expansion

105 clusters · 510 sources · last updated 3 days ago

Latest: Novo Nordisk reports pediatric obesity trial success amid market pressure

Novo Nordisk continues to expand its GLP-1 market presence, maintaining approximately a 43% global market share for obesity and diabetes treatments despite competition from Eli Lilly. The oral Wegovy pill remains a prima

Global pharmaceutical and oncology market growth projections

5 clusters · 7 sources · last updated 4 days ago

Latest: Global cancer therapy markets projected to grow significantly by 2030

The global pharmaceutical and oncology markets are projected to experience substantial growth through the early 2030s, driven by innovative therapies and advancements in diagnostics. While total pharmaceutical spending i

Brazil ANVISA expands product safety enforcement

31 clusters · 228 sources · last updated 5 days ago

Latest: Brazil combats illegal weight-loss drug market as Anvisa fast-tracks generics

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

Eli Lilly acquisition of Merida Biosciences

2 clusters · 19 sources · last updated 11 days ago

Latest: Eli Lilly to acquire Merida Biosciences for up to $2.875 billion

Eli Lilly and Company has entered into a definitive agreement to acquire Merida Biosciences, a biotechnology firm based in Cambridge, Massachusetts, for a total value of approximately $2.88 billion. The deal structure co

Eli Lilly revenue growth and market activity

2 clusters · 3 sources · last updated 11 days ago

Latest: Eli Lilly sees revenue growth driven by GLP-1 therapies

Eli Lilly and Company has experienced significant revenue growth, reporting $23 billion for the second quarter, a 48% year-over-year increase. This growth is primarily attributed to high demand for its GLP-1 metabolic th

FDA approval of Mounjaro for cardiovascular risk

2 clusters · 16 sources · last updated 15 days ago

Latest: FDA approves Eli Lilly's Mounjaro to reduce heart attack and stroke risk

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s diabetes medication, Mounjaro (tirzepatide), to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at

High trading volumes in manufacturing, healthcare, and EV

6 clusters · 6 sources · last updated 23 days ago

Latest: Medical stocks Boston Scientific and McKesson see high trading volume

Market activity continues to show high trading volumes across several key sectors, including manufacturing, pharmaceuticals, electric vehicles, and healthcare. In the manufacturing and semiconductor sectors, significant

Pharmaceutical manufacturing investment trends

4 clusters · 22 sources · last updated about 1 month ago

Latest: Bristol Myers Squibb to invest $2.3B in Houston manufacturing campus

Pharmaceutical companies are making significant investments in manufacturing infrastructure, with a notable focus on expanding capacity within the United States. Eli Lilly and Resilience announced a $750 million partne